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ABSTRACT 
Expression of survivin has been reported to be correlated with shorter survival in patients 
with non-small cell lung cancer (NSCLC), and overexpression of survivin may lead to 
radioresistance in various human cancers. In this study, we inhibited survivin expression 
by using an adenoviral vector (AdsiSurvivin)-mediated RNAi to elucidate the combined 
effect of survivin-targeting gene therapy and radiotherapy on the NSCLC cells. Our data 
revealed that AdsiSurvivin exerted survivin gene silencing, induced apoptosis, and 
significantly attenuated the growth potential in NSCLC cells within 72 hours after 
infection. The combined treatment modalities with AdsiSurvivin infection and radiation 
were significantly more potent on cell-growth inhibition than monotherapy. In H1650, 
H460, A549, and H1975 human NSCLC cells, the survival ratios of AdsiSurvivin-treated 
groups at m.o.i. of 25 and 50 were significantly lower than those of control groups at 
varying radiation dose (0~8 Gy; three-way ANOVA, p < 0.05). The cytotoxicity of 
combined AdsiSurvivin infection and irradiation increased in a dose-dependent manner in 
both the virus and the irradiation treatment. Knockdown of the survivin gene expression 
appears to be a promising treatment strategy for NSCLC. Our data warrants the need for 
further effort to develop survivin-targeted radiosensitizer for lung cancer treatment. 
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INTRODUCTION 
Survivin is a member of the inhibitor of apoptosis family (IAP) that acts as a suppressor 
of apoptosis and plays a critical role in tumor initiation, progression, and drug resistance.1 
High levels of survivin have been found in most human cancers, including cancers of the 
lung, colon, pancreas, prostate, breast, and stomach.2-5 Expression of survivin has been 
reported to be correlated with shorter survival in patients with non-small cell lung cancer 
(NSCLC).3 Survivin is expressed in the G2/M phase in a cell cycle-regulated manner, and 
its interaction with microtubules of mitotic spindle at the beginning of mitosis is essential 
for its antiapoptotic function. Disruption of the survivin-microtubules interaction results 
in the loss of survivin's anti-apoptotic function and increases the caspase-3 activity.6, 7 
Overexpression of survivin has oncogenic potential because it may overcome the G2/M-
phase checkpoint to compel the cell cycle to progress through mitosis.6 In addition, 
survivin overexpression has been shown to result in accelerated S phase shift, resist G1 
arrest, activate cyclin-dependent kinase 2/cyclin E complex and thereby result in Rb 
phosphorylation.8 Moreover, the expression of survivin could be significantly upregulated 
by a sublethal dose of irradiation, which might cause radioresistance.9 Lu et al. reported 
that overexpression of survivin in human embryonic kidney cells (293 cells) prevented 
irradiation-induced apoptosis and increased cell viability after irradiation.10 Increasing 
evidences indicated that the expression of survivin correlated with radioresistance in 
various cancers, thereby implying that survivin may be a potential target for 
radiosensitization during cancer treatment.11-14 
Radiotherapy is commonly used in NSCLC treatment for either curative or palliative 
purposes. However, majority of patients are most likely to suffer regional failure as a part 
of their disease recurrence process.15, 16 Recent researches to improve the clinical 
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outcome in such patients include altered irradiation fraction schedule and the introduction 
of chemotherapy, biotherapy, immunotherapy, virotherapy, or gene therapy on a 
concurrent or adjuvant basis.17-22 Survivin gene expression has been identified in a vast 
majority of NSCLC.3 Additionally, Tamm et al. reported that among all the human tumor 
cells screened, lung cancer cells expressed the highest levels of survivin.23 Since survivin 
overexpression may lead to resistance to radiotherapy by inhibiting apoptosis and 
enhancing cell viability, knockdown of the survivin gene expression by RNA interference 
(RNAi) should be a promising approach to ameliorate the efficacy of radiotherapy during 
NSCLC treatment. In the present study, we inhibited survivin expression by using RNAi 
to elucidate the combined effect of survivin-targeting gene therapy and radiotherapy on 
NSCLC cells. To achieve sufficiently high level of gene suppression in adequately large 
numbers of target cells, we constructed an adenoviral vector expressing short hairpin 
RNA (shRNA) with fold-back stem-loop structure.24 We demonstrate here that the impact 
of adenovirus-mediated transfer of small interfering RNA (siRNA) targeting survivin on 
human NSCLC cells and the potential synergy with irradiation in cell killing. 
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MATERIALS AND METHODS 
Cell Lines 
The NSCLC cell lines A549 (ATCC CCL-185), H460 (ATCC HTB-177), H1650 (ATCC 
CRL-5883), and H1975 (ATCC CRL-5908) were purchased from American Type 
Culture Collection (ATCC; Manassas, Virginia, United States). All were cultured in 
DMEM complete media containing 10% fetal bovine serum (FBS).  
 
Development of Stable 293 Cell Lines with High Survivin Expression 
PcDNA3-Survivin plasmid was constructed by subcloning the fragment of the entire 
survivin encoding gene from plasmid pORF5-hSurvivin (Invivogene, San Diego, CA) 
into the pcDNA3-flag at BamHI site. The vector of pcDNA3-flag was the same as 
previously described.25 Human embryonic kidney cells (E1-transformed; 293 cells) were 
subsequently transfected with pcDNA3-Survivin; transfection was conducted by using a 
liposome-mediated transfection technique with lipofectamine 2000 reagent (Invitrogen, 
Grand Island, NY) and in accordance with the manufacturer's protocol. The transfected 
cells were replated at a 1:20 dilution in DMEM complete media containing 10% FBS and 
1000 μg/ml neomycin (G418; Gibco-BRL Life Technologies Inc, Rockville, MD), and 
cultured for 14 days with replacement of the selective media every 3–4 days. The 
surviving transfectants that were localized in distinct “islands” were then maintained with 
the growth medium. Then, real-time PCR was used to screen the survivin expression of 
individual clones. The stable cell lines with high survivin expression, namely, 293S cells 
were used for further experiments. 
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Adenoviral Vectors 
A 19nt survivin-targeting sequence of oligonucleotides was designed by Oligoengine, Inc. 
(Seattle, WA) and selected as the template: TTCGTCCGGTTGCGCTTTC. By BLAST 
analysis, it was confirmed that the template shared no homology with other coding 
sequences in human beings. A ring sequence of 6 base pairs (ATCGAT) existed between 
the sense and antisense strands. Plasmid pUC-U6, which was kindly gifted by Dr. Tang 
(College of Agriculture and Natural Resources, National Chung Hsing University, 
Taiwan), containing the U6 promoter was inserted between the XhoI and the KpnI sites of 
pUC-18 (Fermentas, Burlington, Ontario, Canada). The siRNA-expressing cassette was 
subcloned into pUC-U6 between the KpnI and the XbaI sites. Then, the XhoI-HindIII 
fragment containing the tandem arranged U6 promoter-driven siRNA expression cassette 
was double enzyme-cut by restriction endonuclease and ligated to the pAdTrack vector.26 
The resultant plasmid was linearized by digesting with restriction endonuclease, and 
subsequently cotransformed into E. coli BJ5183 cells with an adenoviral backbone 
plasmid, pAdEasy-1.26 Recombinants were selected for kanamycin resistance, and 
recombination was confirmed by restriction endonuclease analysis. The linearized 
recombinant plasmid was then transduced into the 293 cells. A recombinant adenovirus 
expressing shRNA against survivin (AdsiSurvivin) was generated. The recombinant 
adenovirus AdCtrl, which carries a green fluorescence protein (GFP) gene regulated by 
the cytomegalovirus (CMV) promoter, was constructed with pAdTrack and pAdEasy-1, 
and used as the control in these experiments.27, 28 These adenovirus vectors were 
amplified by using the 293S cells, and titered by using both Adeno-XTM Rapid Titer Kit 
(BD Biosciences, San Jose, CA) and 293S cells. 
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Western Blot 
Cells (1 × 106) were plated onto 10-cm dishes and incubated for 16 hours at 37°C prior to 
infection. They were subsequently mock-infected or infected with either AdCtrl or 
AdsiSurvivin, and incubated for 24~96 hours. Total cell lysates from the infected cells 
were extracted with lysis buffer (M-PER Mammalian Protein Extraction Reagent; 
Thermo Fisher Scientific Inc, Rockford, IL). The primary antibodies used were mouse 
anti-survivin monoclonal antibody (2802; Cell Signaling Technology, Boston, MA), goat 
anti-γ tubulin polyclonal antibody (sc-7396; Santa Cruz Biotechnology, Santa Cruz, CA), 
and rabbit anti- poly-(ADP-ribose) polymerase (PARP) polyclonal antibody (9542; Cell 
Signaling Technology). Horseradish peroxidase conjugated goat anti-mouse, goat anti-
rabbit, or donkey anti-goat antibody was used as the secondary antibody (Santa Cruz 
Biotechnology). Chemiluminescence detection was carried out by using ECL Plus™ (GE 
Healthcare, Piscataway, NJ) and executed according to the manufacturer’s instructions. 
 
Cellular Proliferation 
Cells (1 × 105/well) were plated in 12-well culture plates and incubated for 16 hours at 
37°C prior to infection. They were then mock-infected or infected with either AdCtrl or 
AdsiSurvivin at varying doses (multiplicity of infection [m.o.i.] of 10, 25, 50, 100, and 
200). On day 1, 2, 3, 4, or 5 after the infection, the remaining cells in the wells were 
collected by trypsinization and suspended in PBS. An equal volume of 0.4% trypan blue 
(Sigma-Aldrich, St. Louis, MO) was added to the cell suspension. Viable cells were 
subsequently determined by direct microscopic counting with trypan blue exclusion. All 
counts were done on triplicate samples. 
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Cell Cycle Analysis 
Cells (1 × 106) were plated onto 10-cm dishes, incubated for 16 hours at 37°C, then 
mock-infected or infected with either AdCtrl or AdsiSurvivin (m.o.i. of 50 each). Five 
days after the infection, the cells were collected by trypsinization, washed twice with 
0.1% glucose in PBS without Mg++ or Ca++ (sample buffer), and then fixed in ice-cold 
70% ethanol overnight at 4°C. Subsequently, the cells were centrifuged for 5 min at 1,500 
rpm. After decanting the 70% ethanol without disturbing the pellet, the cells were stained 
with 50 μg/ml propidium iodide (PI), 100 U/ml RNase A in a sample buffer. The samples 
were subsequently analyzed by two-dimensional flow cytometry (Epics® Ultra™, 
Beckman Coulter, Fullerton, CA) to detect PI. The cell cycles were determined by 
EXPO32 ADC analysis software. 
 
Irradiation 
Cells (1 × 105/well) were plated onto 6-well culture plates and incubated for 16 hours at 
37°C prior to infection. Subsequently, they were mock-infected or infected with either 
AdCtrl or AdsiSurvivin at m.o.i. of 10, 25, or 50. Forty-eight hours after the infection, the 
cells were irradiated (0, 2, 4, or 8 Gy in a single fraction) with a 6-MeV electron beam 
generated by a linear accelerator (Clinac 21EX; Varian, Palo Alto, CA ) at a dose rate of 
300 cGy/min. On day 3 after irradiation, triplet cultures for each combination treatment 
were counted for viable cells. 
 
Statistical Analysis  
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The numeric variables are presented as mean and standard deviation (SD). All statistical 
analyses were performed by using Stata version 10.1 statistical software. (StataCorp. 
2008. Stata Statistical Software: Release 10.1. College Station, TX: StataCorp LP). 
Statistical comparisons were made by using the two-sided t-test. Three-way analysis of 
variance (ANOVA) was used to compare the mean (survival ratios) and the SD at the 
three MOI levels (10, 25, and 50) and varying radiation doses with the treatment of 
AdsiSurvivin or AdCtrl. Two-way ANOVA was used to analyze the data acquired over 
time from both the treatment groups. The first factor was the treatment (AdsiSurvivin vs. 
AdCtrl groups), and the second factor was time (day 3–day 5). Tukey’s HSD test was 
used for pair-wise comparisons. A p value of 0.05 or less indicated significant statistical 
difference. 
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RESULTS 
Survivin expression after treatment with AdsiSurvivin 
We generated stable 293S cell lines containing CMV promoter-controlled survivin 
expression. As illustrated in Fig. 1, the expression of survivin in 293S cells was strongly 
detected by using immunoblotting analysis; further, the expression was markedly higher 
than that observed in the 293 cells. We used the 293S cells to amplify and titer the 
adenoviral vector expressing shRNA against survivin. By using the AdEasy system, we 
generated an adenoviral vector, AdsiSurvivin, which carries both shRNA expression 
cassette for silencing of survivin gene and the GFP gene under control of the U6 
promoter and CMV promoter, respectively. AdCtrl, which is similar to AdsiSurvivin 
except that it lacks the U6 promoter-driven shRNA expression cassette, was used as the 
control vector.26 To evaluate the effect of AdsiSurvivin infection on survivin expression 
in NSCLC cells, we infected the H460, A549, H1650, and H1975 NSCLC cell lines with 
AdsiSurvivin or AdCtrl at m.o.i. of 100 or conducted mock-infection. After a 4-day 
period, survivin expression in the AdsiSurvivin-treated cells was markedly decreased 
than those in the AdCtrl-treated or mock-infected cells (Fig. 2). 
 
Effects of AdsiSurvivin treatment on cell growth 
In order to find an optimal dose for further studies, we treated the H460 and A549 cells 
with varying doses of AdsiSurvivin or AdCtrl (m.o.i. of 0, 10, 25, 50, 100 or 200). At 5 
days, the numbers of viable cells in the AdsiSurvivin-infected group were significantly 
lower than those in the AdCtrl-infected groups even at m.o.i. of 10 in both the cell lines 
(1,025,000 ± 352,232 vs. 1,350,000 ± 178,841 and 575,000 ± 25,000 vs. 1,000,000 ± 
25,000, for H460 and A549 cell lines, respectively; p < 0.0001 in both comparisons), and 
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the cytotoxicity of AdsiSurvivin increased in a dose-dependent manner (Fig. 3). The 
numbers of viable cells in the AdCtrl-infected group were lower than those of the mock-
infected cells for both the cell lines, which indicates the cytotoxicity from the expressed 
viral proteins and the overexpression of GFP. The tested cell lines had different 
sensitivities to this virus-related toxicity. At m.o.i. of 50, the ratios of viable cell numbers 
in the AdCtrl-treated group to those in the mock-infected group (survival ratio) were not 
less than 50% (50.0% ± 3.09% and 64.2% ± 1.89%, respectively) and the ratios of viable 
cell numbers in the AdsiSurvivin-treated group to those in the AdCtrl-infected group 
were not more than 20% (12.9% ± 0.86% and 15.7% ± 1.09%, respectively) in H460 and 
A549 cells. Therefore, we chose the dose of m.o.i. as 50 to examine the effect of 
AdsiSurvivin infection on the cell growth in all the four NSCLC cell lines.   
H460, A549, H1650, and H1975 NSCLC cells were subsequently treated with mock-
infection or infection with AdCtrl or AdsiSurvivin at m.o.i. of 50. The numbers of viable 
cells were counted from day 1 to day 5 after the treatments. As shown in Fig. 4, the 
growth of AdsiSurvivin-infected cells was substantively suppressed by survivin gene 
silencing. Day 3 onwards, the numbers of viable cells in the AdsiSurvivin-infected 
groups were significantly lower than those in the AdCtrl-infected groups in the H460, 
A549, and H1650 cell lines (p = 0.0022, p = 0.00005, and p = 0.00056, respectively). The 
H1975 cells seemed more vulnerable to AdsiSurvivin treatment. The number of viable 
AdsiSurvivin-infected H1975 cells was significantly less than that infected with AdCtrl 
since day 2 (p = 0.0257, Fig. 4D). The cytotoxicity of AdsiSurvivin was significantly 
more potent than that of AdCtrl from day 3 to day 5 in all the four cell lines (two-way 
ANOVA, p < 0.05 in four comparisons). 
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Apoptosis induced by AdsiSurvivin treatment  
In order to assess the apoptosis induced by survivin inhibition, the H460 cells were 
treated with mock-infection, or either AdsiSurvivin or AdCtrl at m.o.i. of 50. On day 5 
following the infection, cell cycle analysis revealed marked increase in the subG1 
population of the AdsiSurvivin-treated cells (Fig. 5A). To confirm the presence of the 
apoptotic process, the H460 cells were also treated with either AdsiSurvivin or AdCtrl at 
m.o.i. of 50; we then examined the cleavage of PARP by Western blot analysis. Day 3 
onwards, degradation of PARP was detected only in the AdsiSurvivin-treated cells, but 
not in the AdCtrl-infected cells (Fig. 5B). The above findings indicated that survivin 
inhibition by siRNA induced programmed cell death, which was accompanied by the 
increased protein cleavage for PARP. 
 
Effects of concurrent treatments of the NSCLC cells with AdsiSurvivin and 
radiation 
We then investigated the cytotoxicity due to the combined effects of radiation and 
survivin inhibition on the NSCLC cells. The H1650, H460, A549, and H1975 lung cancer 
cells were treated with AdsiSurvivin or AdCtrl at m.o.i. of 10, 25, or 50. The culture 
medium alone was used for mock infection. These cells were subsequently treated with 
radiation at 0, 2, 4, or 8 Gy 48 hours after infection. Triplet cultures for each combination 
treatment were counted for the detection of any viable cells on day 3 after the radiation, 
i.e., day 5 after infection. As shown in Fig. 6, increase in the radiation dose significantly 
decreased the survival ratio in a dose-dependent manner in the AdCtrl-infected groups at 
m.o.i. of 10, 25, and 50 in all the four cell lines (three-way ANOVA, p < 0.05 in all the 
12 comparisons). In H460, A549, and H1975 cells, the survival ratios of AdsiSurvivin-
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treated groups at m.o.i. of 10, 25, and 50 were significantly lower than those of the 
AdCtrl-treated groups at varying radiation doses (three-way ANOVA, p < 0.05 in all the 
nine comparisons; Figs. 6B, 6C, and 6D). At m.o.i. of 10, there were no significant 
differences in the survival ratios between AdsiSurvivin and AdCtrl-infected groups in the 
H1650 cells concurrently treated with radiation at varying doses (three-way ANOVA, p = 
0.3571; Fig. 6A). While the viral dose increased to m.o.i. of 25 and 50, the survival ratios 
of the AdsiSurvivin-infected H1650 cells were significantly lower than those of the 
AdCtrl-infected cells concurrently treated with radiation at varying doses (three-way 
ANOVA, p < 0.05 in both comparisons; Fig. 6A). When combined with the treatment of 
AdsiSurvivin at high dose (m.o.i. of 50), irradiation-induced cell killing did not occur in a 
dose-dependent pattern in both the H1650 and A549 cells. The survival ratio was 
significantly higher in non-irradiated A549 cells than when treated with irradiation at 2 
Gy (21.62% ± 4.35% vs. 16.22% ±1.35%, p = 0.002) in high dose AdsiSurvivin-infected 
groups; however, there were no significant differences between the 2-Gy, and 4-Gy, or 8-
Gy radiation (p > 0.05 in both the comparisons, Fig. 6C). In H1650 cells treated with 
AdsiSurvivin at m.o.i. of 50, the survival ratio of the non-irradiated cells was not 
significantly different from those irradiated with 2 Gy or 4 Gy (p > 0.05 in both 
comparisons, Fig. 6A); however, at 8 Gy, there was a significant difference between the 
non-irradiated and irradiated H1650 cells (28.7% ± 0.86% vs. 13.27% ± 1.14%, p = 
0.000046).  
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DISCUSSION 
NSCLC is the leading cause of cancer-related deaths worldwide. Unfortunately, standard 
therapies remain inadequate for attaining disease control. The conventional chemotherapy 
regimens and radiotherapy are more of a hindrance due to their limited efficacy, 
significant toxicity, the development of resistance and high relapse rates; this warrants the 
need for newer therapeutic approaches. More recently, modest success has been achieved 
using novel agents to target signaling transduction pathways, growth factor receptors, 
oncogenes, and tumor-suppressor genes, which are known to become aberrant in lung 
cancer.29 For example, the epidermal growth factor receptor tyrosine kinase inhibitors are 
a major advancement in lung cancer treatment.30, 31 However, the eventual development 
of acquired resistance in the responders also hampers the clinical benefit of these agents 
during NSCLC treatment.32 Therefore, further studies targeting multiple treatment 
modalities and/or the inhibition on multiple signaling pathways are required in our efforts 
to develop a novel therapeutic strategy to enhance anti-cancer efficacy and/or prevent 
drug resistances. Due to the high expression level in NSCLC and significant clinical 
association with survival outcome and treatment resistance, survivin has been widely 
evaluated as a potential therapeutic target for radiation sensitization in lung cancer. By 
using antisense oligonucleotides, several studies have shown the potential of survivin 
inhibition on sensitizing lung cancer cells to radiation.10, 33 In order to achieve such a 
radiosensitization, we combined gene transfer by adenoviral vector and RNAi technology 
to improve the efficacies of both gene transduction and expression inhibition in the 
NSCLC cells. Uchida et al. used adenovirus-mediated transfer of siRNA against survivin 
to induce apoptosis and attenuate tumor cell growth in HeLa, U251, and MCF-7 cells.34 
However, our preliminary data revealed that replication of AdsiSurvivin resulted in 
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marked survivin gene silencing and cell death in both 293 and 293T cells (ATCC CRL-
11268), which resulted in the failure of the virus yield (data not shown). Therefore, we 
generated 293S cells to overcome this toxicity and succeeded in constructing and 
amplifying AdsiSurvivin for further studies. However, the yield of AdsiSurvivin is only 
10% of AdCtrl despite using 293S cells for viral amplification. 
In the present study, our data revealed that AdsiSurvivin successfully exerted survivin 
gene silencing, induced apoptosis, and significantly attenuated the growth potential in 
NSCLC cells. These effects may set in early within 72 hours after infection. Furthermore, 
the effect of combined treatment modalities including AdsiSurvivin infection and 
radiation are significantly more potent on cell-growth inhibition than monotherapy 
involving either one of the above. This synergy was noted even at low virus dose (m.o.i. 
of 10) in most of the cells that were tested. The cytotoxicity of combined AdsiSurvivin 
infection and irradiation increased in a dose-dependent manner for both the treatment 
modalities. However, the increase of radiation dose during concurrent treatment with high 
dose (m.o.i. of 50) of AdsiSurvivin did not increase cell death in A549 and H1650 cells. 
It should be due to the superiority of AdsiSurvivin to irradiation in cytotoxicity at high 
viral dose.  
We demonstrate that the adenovirus-mediated transfer of siRNA against survivin may 
enhance the radiosensitivity of human NSCLC cells. Due to this synergy of survivin gene 
knockdown and irradiation on cell death in NSCLC, this combined treatment modality 
has the potential to improve the anti-cancer efficacy and/or thus reduce radiation dose to 
attenuate collateral damage to normal tissue if applied clinically. Our data warrants the 
need for further effort to develop survivin-targeted radiosensitizer for NSCLC treatment. 
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